

Amendments to the Claims

I. Amendments

Please cancel claims 12-15, without prejudice or disclaimer, as drawn to a non-elected invention.

Please amend the claims as indicated below.

II. The Claims of the Application

- Claim 1. **(Currently amended)** A method of treating a focal muscle spasm, comprising administering, by intramuscular injection, a therapeutically effective dose of an immunotoxin conjugate to a muscle of said focal muscle spasm, wherein said immunotoxin conjugate comprises an antibody conjugated to a ~~muscle~~ **cellular** toxin selected from the group consisting of: ricin and abrin, wherein said antibody is selectively reactive, under immunologically reactive conditions, to a nicotinic acetylcholine receptor; **wherein said antibody of said immunotoxin conjugate binds to a nicotinic acetylcholine receptor of a muscle cell of said muscle, and said cellular toxin of said immunotoxin conjugate mediates the death of said muscle cell.**
- Claim 2. **(Original)** The method of claim 1, wherein the antibody is a monoclonal antibody.
- Claim 3. **(Original)** The method of claim 1, wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.
- Claim 4. **(Previously amended)** The method of claim 1, wherein said muscle toxin is ricin.

- Claim 5. **(Original)** The method of claim 1, wherein the focal muscle spasm is selected from the group consisting of: blepharospasm, cervical dystonia, hand dystonia, limb dystonia, hemifacial spasm, bruxism, strabismus, VI nerve palsy, spasmodic dysphonia, and oromandibular dystonia.
- Claim 6. **(Currently amended)** A method of treating a focal muscle spasm, comprising administering, by intramuscular injection, a therapeutically effective dose of an immunotoxin conjugate to a muscle of said focal muscle spasm, wherein said immunotoxin conjugate comprises an antibody conjugated to a galactose binding moiety and a ~~muscle~~ **cellular** toxin selected from the group consisting of: ricin-A and abrin-A, wherein said antibody is selectively reactive, under immunologically reactive conditions, to a nicotinic acetylcholine receptor;
wherein said antibody of said immunotoxin conjugate binds to a nicotinic acetylcholine receptor of a muscle cell of said muscle, and said cellular toxin of said immunotoxin conjugate mediates the death of said muscle cell.
- Claim 7. **(Original)** The method of claim 6, wherein said galactose binding moiety is selected from the group consisting of: ricin-B and abrin-B.
- Claim 8. **(Original)** The method of claim 6, wherein the antibody is a monoclonal antibody.
- Claim 9. **(Original)** The method of claim 6, wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.
- Claim 10. **(Original)** The method of claim 6, wherein said toxin is ricin.
- Claim 11. **(Original)** The method of claim 6, wherein the focal muscle spasm is selected from the group consisting of: blepharospasm, cervical dystonia,

hand dystonia, limb dystonia, hemifacial spasm, bruxism, strabismus, VI
nerve palsy, spasmodic dysphonia, and oromandibular dystonia.

Claims 12-15. **(Withdrawn)**